DRL Q3 EBITDA seen up 103% to Rs 596 cr

By Ekta Batra, Research Analyst at CNBC-TV18

Pharmaceutial firm Dr Reddy's Laboratories is expected to report a profit after tax of Rs 425 crore in the third quarter of FY12, a massive growth of 55.5% as compared to Rs 273 crore in a year ago quarter.
Revenues are seen going up by 35% to Rs 2,562 crore from Rs 1,899 crore year-on-year.
EBITDA is likely to go up by 103% to Rs 596 crore versus Rs 293.4 cr during the same period.
Operating profit margin is expected to be improving at 23% versus 15.5% year-on-year and 16.5% quarter-on-quarter.
On quarter-on-quarter basis, revenues are seen going up by 13% and EBITDA by 59%. Profit after tax is likely to shot up 38%. Watch out for:
- US business driven by exclusivity will be a key growth driver, hence ripple effect on margins & bottomline
- DRL launched Zyprexa generic with 180 day exclusivity